IL10 and lung carcinoma: These data demonstrate an inherent functional defect in the B-cell-mediated IL-10 response in lung cancer patients who subsequently experience high-grade autoimmune toxicity on checkpoint blockade therapy, linked to the inability to suppress autologous CD4 + Th1 responses.